Cefotaxime is a third-generation cephalosporin and is a broad-spectrum antibiotic. The effect on Gram-negative bacilli is significantly better than that of the first and second-generation cephalosporins, especially against influenza bacillus, Escherichia coli, Enterobacter, Citrobacter, Serratia, Klebsiella and β. - The action of lactamase-resistant Escherichia coli is stronger than that of cefoperazone, and the effect of Haemophilus producing penicillinase is the strongest. Cefotaxime treatment of patients with hematological malignancies has the best clinical response and long duration of bactericidal action, but the bactericidal effect on Pseudomonas aeruginosa and Enterobacter cloacae is poor.
 

Function

1. Lower respiratory tract infections (such as pneumonia).
2. Genitourinary infections (including urinary tract infections, metritis, prostatitis, gonorrhea, etc.).
3. Intraperitoneal infections (such as peritonitis, biliary tract, etc.).
4. Bone, joint, skin and soft tissue infections.
5. Prevention of surgical infections.
6. ENT infection.
7. Other serious infections, such as acute suppurative meningitis (especially infantile meningitis), bacterial endocarditis, sepsis, etc.

Application

Product performance: This product is white or white crystalline powder, odorless, bitter, soluble in water, stable in aqueous solution, can be stored at room temperature for 24 hours.